Basic Information
| RNALocate ID: | RLID:01002336 |
| RNA Symbol: | hsa-miR-494-3p |
| Localization: | Nucleus |
RNA Information
| RNA Name: | hsa-miR-494 |
| RNA ID: | miRBase:MIMAT0002816 |
| RNA Category: | miRNA |
| Species: | Homo sapiens |
Localization Information
| PubMed ID: | 20498841 |
| Tissue/Cell Line: | Nasopharyngeal carcinoma cells |
| Method: | Next-generation RNA sequencing |
| Description: | The expression level of all microRNAs that detected in the nuclear and cytoplasmic 18-30nt sRNA of 293T cell line. Table S5. The N/C values of all isomiRs. The isomiRs are shown only if it displayed a raw read count (non-normalized) more than 10 in at least one library. Data are collected from Table S5, S9. |
Other Subcellular Localization
| RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
| RLID:01002330 | Cytoplasm | Nasopharyngeal carcinoma cells | 20498841 |
| RLID:01002331 | Cytosol | Cell line (HeLa) | 21695135 |
| RLID:01002332 | Mitochondrion | HeLa cells | 27396686 |
| RLID:01002333 | Mitochondrion | HeLa cells | 27563705 |
| RLID:01002334 | Mitochondrion | Cell line (HeLa) | 21695135 |
| RLID:01002335 | Nucleolus | Breast adenocarcinoma cells (MCF-7) | 24918059 |
| RLID:11002989 | Exosome | Breast cancer cell line (MCF-7) | 20976003 |
| RLID:11002990 | Exosome | Primary dendritic cells | 21505438 |
| RLID:11002991 | Exosome | Brain tissue | 23382797 |
| RLID:11002992 | Exosome | Plasma | 23663360 |
| RLID:11002993 | Exosome | Human mast cell line (HMC-1) | 24009880 |
| RLID:11002994 | Exosome | Breast cancer cell lines (MCF-7|MDA-MB-231) | 24468161 |
| RLID:11002995 | Exosome | Serum | 24683445 |
| RLID:11002996 | Microvesicle | Seminal plasma | 23539611 |
| RLID:11002997 | Microvesicle | Follicular fluid | 23666971 |
| RLID-D:11000483 | Microvesicle | Fibroblasts|Mesenchymal stem cells | |
| RLID-D:11001248 | Exosome | Breast milk|Cell lines|Epididymal epithelial cells|Osteoblast|Plasma|Primary glioblastoma neurosphere cells|Primary keratinocyte|Saliva|Serum|Urine |
ncRNA Disease Information
| Resource | RNA Symbol | Disease | Link |
| MNDR | hsa-miR-494-3p | Multiple sclerosis chronic progressive | MNDR-E-MI-54541 |
| MNDR | hsa-miR-494-3p | Oral squamous cell carcinoma | MNDR-E-MI-54542 |
| MNDR | hsa-miR-494-3p | Large cell neuroendocrine cancer | MNDR-E-MI-54543 |
| MNDR | hsa-miR-494-3p | Medulloblastoma | MNDR-E-MI-54544 |
| MNDR | hsa-miR-494-3p | B cell lymphoma of malt type | MNDR-E-MI-54545 |
| MNDR | hsa-miR-494-3p | High-grade serous ovarian carcinoma | MNDR-E-MI-54546 |
| MNDR | hsa-miR-494-3p | Uterine corpus endometrial carcinoma | MNDR-E-MI-54547 |
| MNDR | hsa-miR-494-3p | Lymphoma | MNDR-E-MI-54548 |
| MNDR | hsa-miR-494-3p | Non-hodgkin lymphoma | MNDR-E-MI-54549 |
| MNDR | hsa-miR-494-3p | Estrogen-receptor positive breast cancer | MNDR-E-MI-54550 |
| MNDR | hsa-miR-494-3p | Progesterone-receptor positive breast cancer | MNDR-E-MI-54551 |
| MNDR | hsa-miR-494-3p | Her2-receptor positive breast cancer | MNDR-E-MI-54552 |
| MNDR | hsa-miR-494-3p | Precursor cell lymphoblastic leukemia-lymphoma | MNDR-E-MI-54553 |
| MNDR | hsa-miR-494-3p | B cell acute lymphoblastic leukemia | MNDR-E-MI-54554 |
| MNDR | hsa-miR-494-3p | Prostate cancer | MNDR-E-MI-54555 |
| MNDR | hsa-miR-494-3p | Gastric cancer | MNDR-E-MI-54556 |
| MNDR | hsa-miR-494-3p | Alzheimer disease | MNDR-E-MI-54557 |
| MNDR | hsa-miR-494-3p | Intracranial aneurysm | MNDR-E-MI-54558 |
| MNDR | hsa-miR-494-3p | Bladder cancer | MNDR-E-MI-54559 |
| MNDR | hsa-miR-494-3p | Brucellosis | MNDR-E-MI-54560 |
| MNDR | hsa-miR-494-3p | Dysautonomia familial | MNDR-E-MI-54561 |
| MNDR | hsa-miR-494-3p | Duchenne muscular dystrophy | MNDR-E-MI-54562 |
| MNDR | hsa-miR-494-3p | Primary biliary cirrhosis | MNDR-E-MI-54563 |
| MNDR | hsa-miR-494-3p | Leukemia | MNDR-E-MI-54564 |
| MNDR | hsa-miR-494-3p | Cardiovascular disease | MNDR-E-MI-54565 |
| MNDR | hsa-miR-494-3p | Lung cancer | MNDR-E-MI-54566 |
| MNDR | hsa-miR-494-3p | Down syndrome | MNDR-E-MI-54567 |
| MNDR | hsa-miR-494-3p | Parkinson disease | MNDR-E-MI-54568 |
| MNDR | hsa-miR-494-3p | Breast cancer | MNDR-E-MI-54569 |
| MNDR | hsa-miR-494-3p | Pancreatic cancer | MNDR-E-MI-54570 |
| MNDR | hsa-miR-494-3p | Melanoma | MNDR-E-MI-54571 |
| MNDR | hsa-miR-494-3p | Nephroblastoma | MNDR-E-MI-54572 |
| MNDR | hsa-miR-494-3p | Colon cancer | MNDR-E-MI-54573 |
| MNDR | hsa-miR-494-3p | Colon adenocarcinoma | MNDR-E-MI-54574 |
| MNDR | hsa-miR-494-3p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-54575 |
| MNDR | hsa-miR-494-3p | Ovarian cancer | MNDR-E-MI-54576 |
| MNDR | hsa-miR-494-3p | Prostate adenocarcinoma | MNDR-E-MI-54577 |
| MNDR | hsa-miR-494-3p | Carcinoma ductal breast | MNDR-E-MI-54578 |
| MNDR | hsa-miR-494-3p | Glioblastoma | MNDR-E-MI-54579 |
| MNDR | hsa-miR-494-3p | Glioma | MNDR-E-MI-54580 |
| MNDR | hsa-miR-494-3p | Amyotrophic lateral sclerosis | MNDR-E-MI-54581 |
| MNDR | hsa-miR-494-3p | Temporal lobe epilepsy | MNDR-E-MI-54582 |
| MNDR | hsa-miR-494-3p | Osteosarcoma | MNDR-E-MI-54583 |
| MNDR | hsa-miR-494-3p | Liposarcoma | MNDR-E-MI-54584 |
| MNDR | hsa-miR-494-3p | Liver cancer | MNDR-E-MI-54585 |
| MNDR | hsa-miR-494-3p | Cervical squamous cell carcinoma | MNDR-E-MI-54586 |
| MNDR | hsa-miR-494-3p | Bone-invasive pituitary adenoma | MNDR-E-MI-54587 |
| MNDR | hsa-miR-494-3p | Lung squamous cell carcinoma | MNDR-E-MI-54588 |
| MNDR | hsa-miR-494-3p | Non-small cell lung cancer | MNDR-E-MI-54589 |
| MNDR | hsa-miR-494-3p | Lung adenocarcinoma | MNDR-E-MI-54590 |
| MNDR | hsa-miR-494-3p | Adrenocortical cancer | MNDR-E-MI-54591 |
| MNDR | hsa-miR-494-3p | Ovarian carcinoma | MNDR-E-MI-54592 |
| MNDR | hsa-miR-494-3p | Bladder urothelial carcinoma | MNDR-E-MI-54593 |
| MNDR | hsa-miR-494-3p | Pancreatic adenocarcinoma | MNDR-E-MI-54594 |
| MNDR | hsa-miR-494-3p | Myasthenia gravis autoimmune experimental | MNDR-E-MI-54595 |
| MNDR | hsa-miR-494-3p | Papillary renal cell carcinoma | MNDR-E-MI-54596 |
| MNDR | hsa-miR-494-3p | Clear cell renal cell carcinoma | MNDR-E-MI-54597 |
| MNDR | hsa-miR-494-3p | Biliary tract cancer | MNDR-E-MI-54598 |
| MNDR | hsa-miR-494-3p | Cholangiocarcinoma | MNDR-E-MI-54599 |
| MNDR | hsa-miR-494-3p | Esophageal cancer | MNDR-E-MI-54600 |
| MNDR | hsa-miR-494-3p | Lung small cell carcinoma | MNDR-E-MI-54601 |
| MNDR | hsa-miR-494-3p | Encephalopathy bovine spongiform | MNDR-E-MI-54602 |
| MNDR | hsa-miR-494-3p | Synovial sarcoma | MNDR-E-MI-54603 |
| MNDR | hsa-miR-494-3p | Stomach carcinoma | MNDR-E-MI-54604 |
| MNDR | hsa-miR-494-3p | Head and neck squamous cell carcinoma | MNDR-E-MI-54605 |
| MNDR | hsa-miR-494-3p | Adenoma | MNDR-E-MI-54606 |
| MNDR | hsa-miR-494-3p | Breast invasive carcinoma | MNDR-E-MI-54607 |
| MNDR | hsa-miR-494-3p | Hepatocellular carcinoma | MNDR-E-MI-54608 |
| MNDR | hsa-miR-494-3p | B-cell lymphoma | MNDR-E-MI-54609 |
| MNDR | hsa-miR-494-3p | Retinoblastoma | MNDR-E-MI-54610 |
| MNDR | hsa-miR-494-3p | Hodgkin lymphoma | MNDR-E-MI-54611 |
| MNDR | hsa-miR-494-3p | Burkitt lymphoma | MNDR-E-MI-54612 |
| MNDR | hsa-miR-494-3p | Mouth neoplasms | MNDR-E-MI-54613 |
| MNDR | hsa-miR-494-3p | Gastrointestinal stromal tumor | MNDR-E-MI-54614 |
| MNDR | hsa-miR-494-3p | Nasopharynx carcinoma | MNDR-E-MI-54615 |
| MNDR | hsa-miR-494-3p | Multiple myeloma | MNDR-E-MI-54616 |
| MNDR | hsa-miR-494-3p | Ovarian epithelial cancer | MNDR-E-MI-54617 |
| MNDR | hsa-miR-494-3p | Nasopharyngeal cancer | MNDR-E-MI-54618 |
| MNDR | hsa-miR-494-3p | Prostatic neoplasms | MNDR-E-MI-54619 |
| MNDR | hsa-miR-494-3p | Pseudorabies | MNDR-E-MI-54620 |
| MNDR | hsa-miR-494-3p | Pancreatitis chronic | MNDR-E-MI-54621 |
| MNDR | hsa-miR-494-3p | Stroke lacunar | MNDR-E-MI-54622 |
| MNDR | hsa-miR-494-3p | Tubulovillous adenoma | MNDR-E-MI-54623 |
RNA Interaction Information
| Resource | RNA Symbol | Species | Link | RNALocate ID |
| RNAInter | ARHGAP5 | Homo sapiens | RR00122451 |
TOP